BenevolentAI
在场
BenevolentAI 是一家在股票代码 BAI (GB) 下上市的公司。
高管
查看带有其 31 名主要高管的组织结构图
BenevolentAI 搜索最多的简介
- Joerg Moeller, Chief Executive Officer and Executive Board Member
- Nigel Shadbolt, Director
- John Orloff, Director
高管在BenevolentAI变化
- Kenneth Mulvany 曾任 Deputy Chairman of the Board, 现升职为 Executive Chairman of the Board (新闻发布的2024十月18号).
- Catherine Isted, Chief Financial Officer, 已经离开公司 (新闻发布的2024七月3号).
- Susan Liautaud, Director, 已经离开公司 (新闻发布的2024五月3号).
创建提醒
跟踪 BenevolentAI 的高管变动
生物技术
BenevolentAI 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
BenevolentAI 的最新新闻稿
- Keynote Panel: The benefits of AI within drug discovery
- BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
- BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
- BenevolentAI to present on explainable AI for drug discovery at BioTechX Europe 2024
- BenevolentAI to present on explainable AI for drug discovery at BioTechX Europe 2024
- Interim results for the six months ended 30 June 2024
- Interim results for the six months ended 30 June 2024
- Notice of Interim Results
- Notice of Interim Results
- How AI is transforming drug discovery
- View more press releases Close
关于 BenevolentAI 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Peter Allen 
